


**Swine flu in Israel – an update
October 30, 2009
MECIDS Meeting**

**Itamar Grotto, MD, MPH, PhD
Director, Public Health Services
Ministry of Health
Israel**


Morbidity and mortality in Israel

Remarks	Total cases	Cases in last week	
	4607	347	Confirmed cases
12 are still in ICU	91 (including deaths)	10	Cases in ICU
	37	5	Deaths

Case by disease onset




Cases by week



Influenza like illness

תרשים 1: שיעור פניות בשבוע בשל תחלואה דמוית שפעת, 2009, בהשוואה לממוצע הרב שנתי



3


Worldwide cases and deaths

Deaths	Cases	Country
6.208	547.366	Total
280	No data	EU and EFTA
130	16.945	UK
1.252	58.151	USA
86	12.038	Canada
314	49.370	Mexico
585	9.119	Argentina
136	12.257	Chile
1.395	32.552	Brazil
186	37.039	Australia
19	3.175	New Zealand

* מבוסס על דיווחים לאומיים
 ** מבוסס על דיווחי ה ECDC

3

ILI in the US



7

Antivirals, vaccines and NPI

- Tamiflu for high risk and severe cases (30-35% stockpile, including Relenza)
- No school closure!
- Vaccination priorities: Risk groups <65, pregnant women, healthcare workers:
 - Children ½-3 years: Non-adjuvanted vaccine (Sanofi)
 - Children aged 3-10: 2 doses, GSK vaccine (Pandemrix)
 - 10-65 years: 1 dose, GSK or Novartis vaccine (Focetria)
 - Pregnant women: Non-adjuvanted vaccine (Sanofi)

8

Main activities

- Preparedness for vaccination campaign
- Seasonal influenza vaccination – continues
- Daily teleconference
- Surveillance in Israel and data from the world
- Increasing laboratory capacity to 6 laboratories
- Continues communication for the public and professionals

9

H1N1 vaccines – safety and immunogenicity

H1N1 vaccines in Israel

- Pandemrix™ :GSK
3.75µg of antigen + [AS03 adjuvant](#) –
- Focetria™ :Novartis
7.5µg of antigen + [MF59 adjuvant](#) : –
- :Sanofi-Pasteur
Adjuvant 15 µg of antigen :Panenza® –
- 3.75µg of antigen + AF03 adjuvant :Humenza® –

31

The base for vaccine registration

- Long time experience with seasonal influenza vaccines
- >5 years of development of new H5N1 vaccines and “Mock-up” registration in Europe
- Experience with other vaccines that include same adjuvants (Cervarix, Fludax)
- Clinical trials with H1N1 vaccines (ongoing)
- Post marketing surveillance

32



Vaccine (2008) 26, 2378–2388



available at www.sciencedirect.com



journal homepage: www.elsevier.com/locate/vaccine



Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial

Hans C. Rümke^{a,*}, José-María Bayas^b, José-Ramón de Juanes^c, Covadonga Caso^d, Jan Hendrik Richardus^e, Magda Campins^f, Lars Rombo^g, Xavier Duval^h, Viktor Romanenkoⁱ, Tino F. Schwarz^j, Rustem Fassakhov^k, Francisco Abad-Santos^l, Frank von Sonnenburg^m, Mamadou Draméⁿ, Roland Sänglerⁿ, W. Ripley Ballouⁿ

13

Immunogenicity (H5N1, 2 doses)

Focetria	Pandemrix	גיל
86%	94%	18-60
81%	98%	60 <
100%	-----	3- 1/2
100%	96% מונה: 1/2	3-5
	100% מונה:	
100%	100% מונה: 1/2	6-9
	100% מונה:	
100%	----	9-17

14

Side effects (H5N1 or Fluad)

Focetria		Pandemrix		SE
Adults	Children	Adults	Children	
*18%	47-81%	*11%	*12-25%	(Ex pain*) Local
	32-69%			Systemic
1%	0-7%	0.2%	2-10%	Fever
6%		2.7%	7-13%	Tiredness, loss of appetite, headache
8%		2.3%		Arthralgia/myalgia

Clinical trials with H1N1 vaccines

Panenza/Humenza	Focetria	Pandemrix	Vaccine
750	175	128	N
3-(60<)	18-50	18-60	Age
(60<83%) 93-94%	92%	98.4%	Immunogenicity (1 dose)
As expected	As expected	As expected	SE
-----	EMA	EMA	Registration

Pregnant women

- Pregnant women (2% of the world's population):
- This group appears to be at increased risk for severe disease, potentially resulting in spontaneous abortion and/or death, especially during the second and third trimesters of pregnancy.
- Inactivated nonadjuvanted vaccines similar to most seasonal influenza vaccines are considered the preferred option given the extensive safety data on their use in pregnant women.
- However, if such a product is not available, pregnant women should be vaccinated with another pandemic influenza vaccine available at that time, for example, an adjuvanted inactivated influenza vaccine or a live attenuated influenza vaccine